We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against firms ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Moderna reports larger-than-expected quarterly loss Revenue falls 66% but beats expectations FDA pauses norovirus vaccine trial after adverse event report Feb 14 (Reuters) - Moderna (MRNA.O ...

(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a rare neurological side effect was reported. The trial of the ...

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down ...

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion ...

Moderna swung to a loss in the last three months of the year after an early launch of its updated Covid-19 vaccine shifted sales out of the fourth quarter. The maker of the Spikevax Covid-19 ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

Here's what you need to know about the possible next generation of shots. Moderna's combo flu and COVID vaccine provided a strong immune response in older adults, with levels comparable to getting ...

Revenue was 4% higher than forecasts, mostly due to higher than expected sales of Moderna’s Covid vaccine, SpikeVax. In January, the company cut its sales guidance for 2025 by $1 billion to $1.5 ...